A detailed history of Cibc World Market Inc. transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Cibc World Market Inc. holds 200,492 shares of DCTH stock, worth $2.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
200,492
Previous 229,074 12.48%
Holding current value
$2.41 Million
Previous $1.92 Million 5.58%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$7.36 - $11.0 $210,363 - $314,402
-28,582 Reduced 12.48%
200,492 $1.81 Million
Q2 2024

Aug 07, 2024

SELL
$4.47 - $8.37 $139,490 - $261,194
-31,206 Reduced 11.99%
229,074 $1.92 Million
Q1 2024

May 13, 2024

SELL
$3.72 - $5.09 $4,274 - $5,848
-1,149 Reduced 0.44%
260,280 $1.24 Million
Q4 2023

Feb 13, 2024

BUY
$2.25 - $4.17 $43,533 - $80,681
19,348 Added 7.99%
261,429 $1.09 Million
Q3 2023

Nov 13, 2023

BUY
$3.12 - $5.85 $366,175 - $686,579
117,364 Added 94.1%
242,081 $980,000
Q2 2023

Aug 11, 2023

BUY
$5.38 - $7.96 $117,741 - $174,204
21,885 Added 21.28%
124,717 $727,000
Q1 2023

May 12, 2023

BUY
$3.46 - $6.0 $80,621 - $139,806
23,301 Added 29.3%
102,832 $591,000
Q4 2022

Feb 13, 2023

SELL
$2.59 - $3.71 $9,425 - $13,500
-3,639 Reduced 4.38%
79,531 $286,000
Q3 2022

Nov 10, 2022

SELL
$3.1 - $4.8 $1,801 - $2,788
-581 Reduced 0.69%
83,170 $266,000
Q2 2022

Aug 10, 2022

SELL
$3.62 - $6.55 $18,100 - $32,750
-5,000 Reduced 5.63%
83,751 $334,000
Q1 2022

May 12, 2022

BUY
$5.64 - $7.95 $19,356 - $27,284
3,432 Added 4.02%
88,751 $568,000
Q4 2021

Feb 14, 2022

BUY
$7.2 - $11.72 $614,296 - $999,938
85,319 New
85,319 $661,000

Others Institutions Holding DCTH

About DELCATH SYSTEMS, INC.


  • Ticker DCTH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 8,597,680
  • Market Cap $103M
  • Description
  • Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...
More about DCTH
Track This Portfolio

Track Cibc World Market Inc. Portfolio

Follow Cibc World Market Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc World Market Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cibc World Market Inc. with notifications on news.